83
Participants
Start Date
June 1, 2016
Primary Completion Date
December 14, 2019
Study Completion Date
December 20, 2019
Mocetinostat - 50 mg
Participants received mocetinostat three times weekly as an oral capsule.
Mocetinostat - 70 mg
Participants received mocetinostat three times weekly as an oral capsule.
Mocetinostat - 90 mg
Participants received mocetinostat three times weekly as an oral capsule.
Mocetinostat - Recommended Phase 2 Dose (70 mg)
Participants received mocetinostat three times weekly as an oral capsule, at the dose recommended after Phase 1 (70 mg).
Durvalumab - 1500 mg
Participants received durvalumab as an intravenous infusion every 4 weeks.
Montefiore Medical Center, The Bronx
Virginia Cancer Specialists, Fairfax
Shenandoah Oncology - Winchester, Winchester
Woodlands Medical Specialists - Pensacola, Pensacola
Southern Cancer Center, PC, Mobile
Sarah Cannon Research Institute, Nashville
Unniversity of Minnesota Masonic Cancer Center, Minneapolis
NorthShore University Health System, Evanston
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Texas Oncology-Plano West, Plano
Mary Crowley Cancer Research Centers, Dallas
Texas Oncology - Denton South, Denton
David Geffen School of Medicine at UCLA, Los Angeles
Seattle Cancer Care Alliance, Seattle
Hackensack University Medical Center, Hackensack
Lead Sponsor
Mirati Therapeutics Inc.
INDUSTRY